Prognostic significance of the bromodeoxyuridine labeling index in primary colorectal carcinoma.
The bromodeoxyuridine (BrdU) labeling index was determined in 40 primary colorectal carcinomas by DNA flow cytometry using a BrdU-specific monoclonal antibody. The labeling index, or the fraction of cells in the S-phase of the cell cycle, ranged from 12% to 52%, with a mean of 28% (SEM, 2%). The labeling index in 19 patients was over 30%, which was termed a higher labeling index. There was no significant difference in the labeling index based on the clinical stage of the disease. During the 5-year follow-up after the apparently curative resection, 14 patients died of the disease, 1 died of an unrelated cause, 1 is alive with a recurrence of the disease, and 24 are alive without the disease. The higher labeling index was thus associated with a significantly poorer patient survival (P = 0.03 based on the generalized Wilcoxon test). The present study therefore disclosed that the S-phase fraction of tumor cells thus determined had prognostic significance in primary colorectal carcinoma.
Kitagawa
T
T
Second Department of Surgery, Mie University School of Medicine, Tsu, Japan.
Matsumoto
K
K
Iriyama
K
K
Suzuki
H
H
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D001973:Bromodeoxyuridine; D015179:Colorectal Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000601:surgery; D004273:DNA, Neoplasm / Q000032:analysis*; D005260:Female; D005434:Flow Cytometry; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016196:S Phase / Q000502:physiology; D016019:Survival Analysis
D000911:Antibodies, Monoclonal; D004273:DNA, Neoplasm; D001973:Bromodeoxyuridine